These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29419393)

  • 21. Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors.
    Cicero AFG; Toth PP; Fogacci F; Virdis A; Borghi C
    Nutr Metab Cardiovasc Dis; 2019 May; 29(5):527-529. PubMed ID: 30954414
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statement for Appropriate Clinical Use of PCSK9 Inhibitors.
    Nohara A; Ohmura H; Okazaki H; Ogura M; Kitagawa K; Koseki M; Sato K; Tsukamoto K; Yamashita S;
    J Atheroscler Thromb; 2018 Aug; 25(8):747-750. PubMed ID: 29899173
    [No Abstract]   [Full Text] [Related]  

  • 24. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
    Landmesser U; Chapman MJ; Stock JK; Amarenco P; Belch JJF; Borén J; Farnier M; Ference BA; Gielen S; Graham I; Grobbee DE; Hovingh GK; Lüscher TF; Piepoli MF; Ray KK; Stroes ES; Wiklund O; Windecker S; Zamorano JL; Pinto F; Tokgözoglu L; Bax JJ; Catapano AL
    Eur Heart J; 2018 Apr; 39(14):1131-1143. PubMed ID: 29045644
    [No Abstract]   [Full Text] [Related]  

  • 25. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid resolution of xanthelasmas after treatment with alirocumab.
    Civeira F; Perez-Calahorra S; Mateo-Gallego R
    J Clin Lipidol; 2016; 10(5):1259-61. PubMed ID: 27678444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy.
    Rallidis LS; Triantafyllis AS; Iliodromitis E
    Hellenic J Cardiol; 2018; 59(5):293-295. PubMed ID: 29128548
    [No Abstract]   [Full Text] [Related]  

  • 28. Familial hypercholesterolaemia: different perspectives.
    Jones JL; Lakasing E; Archontakis S
    Nurs Stand; 2009 Aug 19-25; 23(50):35-8. PubMed ID: 19736707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCSK9 inhibitors.
    Farnier M
    Curr Opin Lipidol; 2013 Jun; 24(3):251-8. PubMed ID: 23652470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic screening for familial hypercholesterolemia identifies patients not meeting cholesterol treatment guidelines.
    Jones LK; Jefferson CR; Chen N; Murray MF
    Coron Artery Dis; 2021 Sep; 32(6):588-589. PubMed ID: 33394692
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury SR; Rees A
    Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical manifestations of heterozygote familial hypercholesterolemia in Spain. Study of 301 cases from the central and northern areas].
    Garcés C; Rodríguez Artalejo F; Serrano A; González Bonillo J; Almagro F; Garrido JA; Zúñiga M; de Oya M
    Med Clin (Barc); 2000 Jan; 114(2):50-1. PubMed ID: 10702948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hypercholesterolemia].
    Mabuchi H
    Nihon Naika Gakkai Zasshi; 1992 Nov; 81(11):1760-6. PubMed ID: 1479215
    [No Abstract]   [Full Text] [Related]  

  • 35. [60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
    MMW Fortschr Med; 2001 Nov; 143(44):60. PubMed ID: 11732408
    [No Abstract]   [Full Text] [Related]  

  • 36. ["Gout tophi" and heart disease in the family].
    Widmer Ch; Hättenschwiler A; Gross B; Schulthess G
    Praxis (Bern 1994); 2003 Nov; 92(45):1912-5. PubMed ID: 14639818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
    Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
    J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Stein EA; Mellis S; Yancopoulos GD; Stahl N; Logan D; Smith WB; Lisbon E; Gutierrez M; Webb C; Wu R; Du Y; Kranz T; Gasparino E; Swergold GD
    N Engl J Med; 2012 Mar; 366(12):1108-18. PubMed ID: 22435370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [PCSK9 inhibition--A new era in cholesterol treatment].
    Olsson A
    Lakartidningen; 2015 Feb; 112():. PubMed ID: 25689006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.